Published Date: 16 Feb 2023
Although there are concerns that the use of Paxlovid increases the risk of COVID-19 returning, the results are clear.
Read Full NewsQurAlis reported interim ANQUR trial results showing target engagement, a biomarker signal, and a trend toward slower functional decline with QRL-201 in ALS.
Servier reported that sevasemten did not meet its primary or secondary endpoints in the pivotal GRAND CANYON trial for Becker muscular dystrophy.
GLP-1 RAs Linked to Lower Diabetes, CV Risk than Metformin in Prediabetes
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation